672.93
+3.03%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medpace Holdings
From its filings with the US Securities and Exchange Commission
Medpace Holdings is based in Cincinnati, Ohio and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MEDP. The SEC classifies its business as commercial physical & biological research. In the fiscal year to 31 December 2025, it reported revenue of $2.53bn and net income of $451.1m. At that date it held total assets of $1.98bn and shareholders' equity of $459.1m. By business, Oncology brought in 29.5% of revenue, followed by Other at 29.4% and Metabolic at 16.1%.
We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics. We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our therapeutic expertise. We believe this combination results in timely and cost-effective delivery of clinical development services for our customers. We believe that we are a partner of choice for small and mid-sized biopharmaceutical companies based on our ability to consistently utilize our full-service, disciplined operating model to deliver timely and high-quality results for our customers. Accordingly, our business strategy aims to continue to expand our market share in the growing Phase I-IV CRO market as we conduct clinical trials across all major therapeutic areas, with particular strength in Oncology, Metabolic, Cardiology, Antiviral and Anti-infective (AVAI) and Central Nervous System (CNS).
Quoted from its 10-K, filed 10 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 11 Aug 2016
- Employees
- 6,200
- Head office
- 5375 MEDPACE WAY, CINCINNATI, OH, 45227
- Incorporated in
- DE
- Classification
- Services-Commercial Physical & Biological Research
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. August TroendleChairman of the Board, Chief Executive Officer, since 1992$8.6m
- Mr. Jesse GeigerPresident$4.7m
- Mr. Kevin BradyChief Financial Officer, Treasurer$3.5m
- Ms. Susan BurwigExecutive Vice President - Operations$4.8m
- Mr. Stephen EwaldGeneral Counsel, Corporate Secretary$3.7m
- Mr. Fred DavenportLead Independent Director$264,916
- Mr. Brian CarleyIndependent Director$234,651
- Dr. Femida Gwadry-SridharIndependent Director$209,916
- Mr. Robert KraftIndependent Director$227,342
- Mr. Cornelius MccarthyIndependent Director$217,325
- Dr. Dani ZanderIndependent Director$161,497
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 69
- Environment
- 53
- Social
- 99
- Governance
- 55
- Women in the workforce
- 67%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Medpace Holdings Inc has several strengths that contribute to its success in the market. Firstly, the company has a strong reputation and expertise in the clinical research and development industry. This positions Medpace as a trusted partner for pharmaceutical and biotechnology companies, leading to a solid customer base and long-term collaborations.
- Additionally, Medpace possesses a highly skilled and dedicated workforce. The company's employees are experienced professionals who provide outstanding support and guidance throughout the clinical trial process. This expertise allows Medpace to deliver high-quality services, ensuring accurate and reliable results for clients.
Weaknesses
- Despite its strengths, Medpace Holdings Inc faces certain weaknesses that could pose challenges. One notable weakness is the company's geographic concentration. Medpace primarily operates in North America and Europe, which limits its market reach compared to competitors with a more global presence. This makes it vulnerable to regional economic fluctuations and regulatory changes.
- Another weakness is that Medpace relies heavily on a few key clients for a significant portion of its revenue. This client concentration exposes the company to the risk of losing a major customer, potentially leading to a decline in revenue and profitability.
Opportunities
- There are several opportunities available to Medpace Holdings Inc that can enable further growth and expansion. Firstly, the increasing demand for clinical research and development presents a significant opportunity for Medpace to capitalize on. As the pharmaceutical and biotechnology industries continue to evolve, there is a growing need for reliable clinical trial services, which Medpace is well-positioned to provide.
- Additionally, Medpace can explore opportunities to expand into emerging markets. By establishing a presence in regions like Asia and Latin America, the company can tap into new customer segments and diversify its revenue streams. This would reduce its reliance on specific geographic markets and open up potential growth avenues.
Threats
- Medpace Holdings Inc is not immune to threats that could impact its performance and market position. External competition is a key threat, as the clinical research and development industry is highly competitive. Medpace must continuously innovate and differentiate itself to stay ahead of competitors and maintain its market share.
- Moreover, regulatory and legal uncertainties pose a threat to Medpace's operations. Changes in regulations pertaining to clinical trials or data privacy can significantly impact the company's ability to conduct its business smoothly. Medpace must closely monitor and adapt to changes in the regulatory landscape to mitigate this threat effectively.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.